Ischemic placental syndrome – prediction and new disease monitoring

References

• Michalski U, Bauer W, Gojowczyk R, et al. A rare differential diagnosis of a pregnancy gestosis. Dtsch Med Wochenschr 1999;124:1164–7
   PubMed Web of Science ®Google Scholar
• Torbé A, Chłapowska E, Szymańska-Pasternak J, et al. Urinary lysosomal enzyme excretion in pregnant women with hypertensive disorders. Hypertens Pregn 2014;33:349–59
   PubMed Web of Science ®Google Scholar
• Kwiatkowski S, Rzepka R, Torbé A, et al. Severe preeclampsia: differences in the management according to gestational age. Arch Perinat Med 2011;17:223–8
   Google Scholar
• Kwiatkowski S, Kwiatkowska E, Czajka R, et al. The activity of erythrocyte sodium-proton exchanger in women with pregnancy- induced hypertension. Hypertens Pregn 2006;25:37–46
   PubMed Web of Science ®Google Scholar
• Figueras F, Gratacos E. Stage-based approach to the management of fetal growth restriction. Prenat Diagn 2014;34:655–9
   PubMed Web of Science ®Google Scholar
• Marcorelles P. Placental features in intrauterine growth retardation. J Gynecol Obstet Biol Reprod (Paris) 2013;42:996–1007
   PubMed Web of Science ®Google Scholar
• Kovo M, Schreiber L, Bar J. Placental vascular pathology as a mechanism of disease in pregnancy complications. Thromb Res 2013;131:S18–21
   PubMed Web of Science ®Google Scholar
• Copel JA, Bahtiyar MO. A practical approach to fetal growth restriction. Obstet Gynecol 2014;123:1057–69
   PubMed Web of Science ®Google Scholar
• Ananth CV, Williams MA. Placental abruption and placental weight—implications for fetal growth. Acta Obstet Gynecol Scand 2013;92:1143–50
   PubMed Web of Science ®Google Scholar
• Samantha EP, Martha MW. Epidemiology of ischemic placental disease: a focus on preterm gestations. Semin Perinatol 2014;38:133–8
   PubMed Web of Science ®Google Scholar
• Cande VA. Ischemic placental disease: a unifying concept for preeclampsia, intrauterine growth restriction, and placental abruption. Semin Perinatol 2014;38:131–2
   PubMed Web of Science ®Google Scholar
• Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 2013;166:117–23
   PubMed Web of Science ®Google Scholar
• Vintzileos M, Ananth CV. First trimester prediction of ischemic placental disease. Semin Perinatol 2014;38:159–66
   PubMed Web of Science ®Google Scholar
• Rasanen J, Quinn MJ. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol 2015;2:82.e1–9
   Web of Science ®Google Scholar
• Imdad A, Sheikh L, Malik A. Atypical eclampsia. J Pak Med Assoc 2009;59:489–90
   PubMedGoogle Scholar
• Bixel K, Silasi M, Zelop CM, et al. Placental origins of angiogenic dysfunction in mirror syndrome. Hypertens Pregn 2012;31:211–17
   PubMed Web of Science ®Google Scholar
• Pijnenborg R, Dixon G, Robertson W, Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980;1:3–19
   PubMed Web of Science ®Google Scholar
• Zhou Y, Damsky C, Fischer S. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99:2152–64
   PubMed Web of Science ®Google Scholar
• Roberts DJ, Post MD. The placenta in preeclampsia and intrauterine growth restriction. J Clin Pathol 2008;61:1254–60
   PubMed Web of Science ®Google Scholar
• Matsubara K, Higaki T, Matsubara Y, Nawa A. Nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. Int J Mol Sci 2015;16:4600–14
   PubMed Web of Science ®Google Scholar
• Molvarec1 A, Szarka A, Walentin Sz, Bekő G. Serum leptin levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in normal pregnancy and preeclampsia. Reprod Biol Endocrinol 2011;9:124
   PubMed Web of Science ®Google Scholar
• Reimer T, Rohrmann T, Stubert J. Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis. J Maternal–Fetal Neonat Med 2013;26:263–9
   PubMed Web of Science ®Google Scholar
• Pratt A, Da Silva Costa F, Borg AJ. Placenta-derived angiogenic proteins and their contribution to the pathogenesis of preeclampsia. Angiogenesis 2015;18:115–23
   PubMed Web of Science ®Google Scholar
• Hoeben A, Landuyt B, Highley M, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549–80
   PubMed Web of Science ®Google Scholar
• Brkovic A, Sirois MG. Vascular permeability induced by VEGF family members in vivo: role of endogenous PAF and NO synthesis. J Cell Biochem 2007;100:727–37
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of preeclampsia. J Matern Fetal Neonatal Med 2005;17:3–18
   PubMed Web of Science ®Google Scholar
• Wilczyński JR. Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia – the same basic mechanism? Human Immunol 2006;67:492–511
   PubMed Web of Science ®Google Scholar
• Cerdeira AS, Karumanchi SA. Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med 2012;2:a006585
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013;208:287. e1-287.e15
   PubMed Web of Science ®Google Scholar
• Roberts JM, Bell MJ. If we know so much about preeclampsia, why haven't we cured the disease? J Reprod Immunol 2013;99:1–9
   PubMed Web of Science ®Google Scholar
• Heilmann L, Rath W, Pollow K. Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost 2007;13:285–91
   PubMed Web of Science ®Google Scholar
• Prochazkova J, Slavik L, Ulehlova J, Prochazka M. The role of tissue factor in normal pregnancy and in the development of preeclampsia: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:192–6
   PubMed Web of Science ®Google Scholar
• Ananth CV, Vintzileos AM. Ischemic placental disease: epidemiology and risk factors. Eur J Obstet Gynecol Reprod Biol 2011;159:77–82
   PubMed Web of Science ®Google Scholar
• Wagner SJ, Craici IM, Grande JP, Garovic VD. From placenta to podocyte: vascular and podocyte pathophysiology in preeclampsia. Clin Nephrol 2012;78:241–9
   PubMed Web of Science ®Google Scholar
• Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 2008;29:1043–9
   PubMed Web of Science ®Google Scholar
• Robert LG, Elizabeth MM. Maternal, fetal and neonatal mortality: lessons learned from historical changes in high income countries and their potential application to low-income countries. Matern Health, Neonatol Perinatol 2015;1:3
   Google Scholar
• Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol 2006;195:1557–63
   PubMed Web of Science ®Google Scholar
• Romberger DJ. Fibronectin. Int J Biochem Cell Biol 1997;29:939–43
   PubMed Web of Science ®Google Scholar
• Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4:700–8
   PubMed Web of Science ®Google Scholar
• Aydin T, Varol FG, Sayin NC. Third trimester maternal plasma total fibronectin levels in pregnancy-induced hypertension: results of a tertiary center. Clin Appl Thromb Hemost 2006;12:33–39
   PubMed Web of Science ®Google Scholar
• Dane C, Buyukasik H, Dane B, Yayla M. Maternal plasma fibronectin and advanced oxidative protein products for the prediction of preeclampsia in high risk pregnancies: a prospective cohort study. Fetal Diagn Ther 2009;26:189–94
   PubMed Web of Science ®Google Scholar
• Biskupska Bodovaa K, Biringera K, Dokusa K. Fibronectin, plasminogen activator inhibitortype 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia. Disease Mark 2011;30:191–6
   PubMed Web of Science ®Google Scholar
• Wang Z, Xiong G, Zhu Y. The predictive value of plasma fibronectin concentration on fetal growth retardation at earlier stage of the third trimester. J Tongji Med Univ 2001;21:253–5
   PubMedGoogle Scholar
• Friedman SA, de Groot CJ, Taylor RN, et al. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1994;170:838–41
   PubMed Web of Science ®Google Scholar
• Tjoa ML, Oudejans CB, van Vugt JM, et al. Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens Pregn 2004;23:171–89
   PubMed Web of Science ®Google Scholar
• Dreyfus M, Baldauf JJ, Ritter J, et al. The prediction of preeclampsia: reassessment of clinical value of increased plasma levels of fibronectin. Eur J Obstet Gynecol Reprod Biol 1998;78:25–8
   PubMed Web of Science ®Google Scholar
• Madazli R, Kuseyrioglu B, Uzun H, et al. Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2005;89:251–7
   PubMed Web of Science ®Google Scholar
• Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 2015;24:131–8
   PubMed Web of Science ®Google Scholar
• Teran E, Escudero C, Calle A. C-reactive protein during normal pregnancy and pre-eclampsia. Int J Gynaecol Obstet 2005;89:299–300
   PubMed Web of Science ®Google Scholar
• McElrath TF, Allred EN, Van Marter L, et al. ELGAN Study Investigators. Perinatal systemic inflammatory responses of growth-restricted preterm newborns. Acta Paediatr 2013;102:e439–42
   PubMed Web of Science ®Google Scholar
• Raghupathy R, Al-Azemi M, Azizieh F. Intrauterine growth restriction: cytokine profiles of trophoblast antigen-stimulated maternal lymphocytes. Clin Dev Immunol 2012;2012:734865
   PubMedGoogle Scholar
• Yan-Qiong Ouyang, Si-Jian Li, Qing Zhang. Plasma sFlt-1-to-PlGF ratio is correlated with inflammatory but not with oxidative stress in Chinese preeclamptic women. Arch Gynecol Obstet 2009;280:91–7
   PubMed Web of Science ®Google Scholar
• Windsperger K, Lehner R. The fibrinogen/CRP ratio as a new parameter for the diagnosis of disseminated intravascular coagulation in patients with HELLP syndrome and as a predictive factor for neonatal outcome. Am J Obstet Gynecol 2013;208:118.e1–7
   PubMed Web of Science ®Google Scholar
• Jacobs M, Nassar N, Roberts CL, et al. Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol 2011;9:77
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38
   PubMed Web of Science ®Google Scholar
• Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–19
   PubMed Web of Science ®Google Scholar
• Hanita O, Alia NN, Zaleha AM, Nor Azlin MI. Serum soluble FMS-like tyrosine kinase 1 and placental growth factor concentration as predictors of preeclampsia in high risk pregnant women. Malays J Pathol 2014;36:19–26
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for still birth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013;208:e1–15
   Web of Science ®Google Scholar
• Machado JS, Machado MS, Bertagnolli TV, et al. Assessment of concentrations of sFlt-1 and PlGF as predictors of preeclampsia. Pregn Hypertens 2015;5:58
   Google Scholar
• Stepan H, Herraiz I, Schlembach D, et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015;45:241–6
   PubMed Web of Science ®Google Scholar
• Hirashima C, Ohkuchi A, Takahashi K, et al. A novel three-step approach for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. Hypertens Res 2014;37:519–25
   PubMed Web of Science ®Google Scholar
• Bakalis S, Gallo DM, Mendez O, et al. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30–34 weeks. Ultrasound Obstet Gynecol 2015;46:208–15
   PubMed Web of Science ®Google Scholar
• Herraiz I, Dröge LA, Gómez-Montes E, et al. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol 2014;124:265–73
   PubMed Web of Science ®Google Scholar
• Alahakoon TI, Zhang W, Trudinger BJ, Lee VW. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. J Matern Fetal Neonatal Med 2014;27:1854–9
   PubMed Web of Science ®Google Scholar
• Signore C, Mills JL, Qian C, et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006;108:338–44
   PubMed Web of Science ®Google Scholar
• Signore C, Mills JL, Qian C, et al. Circulating soluble endoglin and placental abruption. Prenat Diagn 2008;28:852–8
   PubMed Web of Science ®Google Scholar
• Llurba E, Marsal G, Sanchez O, et al. Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. Ultrasound Obstet Gynecol 2012;40:367–9
   PubMed Web of Science ®Google Scholar
• Stubert J, Ullmann S, Bolz M, et al. Prediction of preeclampsia and induced delivery at 34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis. BMC Pregn Childbirth 2014;14:292
   PubMed Web of Science ®Google Scholar
• Pinheiro CC, Rayol P, Gozzani L, et al. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenat Diagn 2014;34:1084–92
   PubMed Web of Science ®Google Scholar
• Staff AC, Redman CWG. IFPA Award in Placentology Lecture: preeclampsia, the decidual battleground and future maternal cardiovascular disease. Placenta 35, supplement A. Trophoblast Res 2014;28:S26–eS31
   Google Scholar
• Garcia-Tizon Larroca S, Tayyar A, Poon LC, et al. Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30–33 weeks' gestation. Fetal Diagn Ther 2014;36:9–17
   PubMed Web of Science ®Google Scholar
• Poon LC, Nicolaides KH. Early prediction of preeclampsia. Obstet Gynecol Int 2014;2014:297397
   PubMedGoogle Scholar
• Oliveira N, Magder LS, Blitzer MG, Baschat AA. First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol 2014;44:279–85
   PubMed Web of Science ®Google Scholar
• Odibo AO, Goetzinger KR, Odibo L, Tuuli MG. Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: a randomized controlled trial. Ultrasound Obstet Gynecol 2015. [Epub ahead of print]. doi: 10.1002/uog.14889
   Web of Science ®Google Scholar
• Park F, Russo K, Williams P, et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol 2015. [Epub ahead of print]. doi: 10.1002/uog.14819
   Web of Science ®Google Scholar
• Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141–6
   PubMed Web of Science ®Google Scholar
• Leung KY, Poon CF, Teotico AR, et al. Ultrasound Committee, Asia and Oceania Federation of Obstetrics & Gynaecology. Recommendations on routine mid-trimester anomaly scan. J Obstet Gynaecol Res 2015;41:653–61
   PubMed Web of Science ®Google Scholar
• Antenatal care: routine Care for the healthy pregnant woman. National Collaborating Centre for Women's and Children's Health (UK). London: RCOG Press; 2008
   Google Scholar
• Papageorghiou AT, Yu CKH, Bindra R, et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:441–9
   PubMed Web of Science ®Google Scholar
• Parra M, Rodrigo R, Barja P, et al. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005;193:1486–91
   PubMed Web of Science ®Google Scholar
• Napolitano R, Melchiorre K, Arcangeli T, et al. Screening for pre-eclampsia by using changes in uterine artery Doppler indices with advancing gestation. Prenat Diagn 2012;32:180–4
   PubMed Web of Science ®Google Scholar
• Kim HK, Lee DS, Kang SH, et al. Utility of the fibrinogen/C-reactive protein ratio for the diagnosis of disseminated intravascular coagulation. Acta Haematol 2007;117:34–9
   PubMed Web of Science ®Google Scholar
• Kumru S, Godekmerdan A, Kutlu S, Ozcan Z. Correlation of maternal serum high-sensitive C-reactive protein levels with biochemical and clinical parameters in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2006;124:164–7
   PubMed Web of Science ®Google Scholar
• Tjoa ML, van Vugt JM, Go AT, et al. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J Reprod Immunol 2003;59:29–37
   PubMed Web of Science ®Google Scholar
• van Runnard Heimel PJ, Kavelaars A, Heijnen CJ, et al. HELLP syndrome is associated with an increased inflammatory response, which may be inhibited by administration of prednisolone. Hypertens Pregn 2008;27:253–65
   PubMed Web of Science ®Google Scholar
• Hund M, Verhagen-Kamerbeek W, Reim M, et al. Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia–the PreOS study protocol. Hypertens Pregn 2015;34:102–15
   PubMed Web of Science ®Google Scholar
• Lobmaier SM, Figueras F, Mercade I, et al. Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-for-gestational-age fetuses. Ultrasound Obstet Gynecol 2014;43:533–40
   PubMed Web of Science ®Google Scholar
• Schoofs K, Grittner U, Engels T, et al. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med 2014;42:61–8
   PubMed Web of Science ®Google Scholar
• Lai J, Garcia-Tizon Larroca S, Peeva G, et al. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther 2014;35:240–8
   PubMed Web of Science ®Google Scholar
• Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med 2013;41:511–16
   PubMed Web of Science ®Google Scholar